内源性逆转录病毒:肺腺癌治疗中一个颇具前景的新靶点  

ERV: a promising new target for lung adenocarcinoma treatment

作　　者：孙思远 方冰 王然 任发政 陈娟 Siyuan Sun;Bing Fang;Ran Wang;Fazheng Ren;Juan Chen(Key Laboratory of Precision Nutrition and Food Quality,Department of Nutrition and Health,China Agricultural University,Beijing 100190,China)

机构地区：[1]Key Laboratory of Precision Nutrition and Food Quality,Department of Nutrition and Health,China Agricultural University,Beijing 100190,China

出　　处：《Science Bulletin》2023年第19期2135-2138,M0003,共5页科学通报（英文版）

基　　金：the National Natural Science Foundation of China(31970611);the Chinese Universities Scientific Fund(2023TC016)。

摘　　要：Lung cancer is a deadly disease,being the most common of all cancer forms.In 2020,there are more than 1.8 million deaths caused by lung cancer worldwide[1].Among all cases,patients with non-small cell lung cancer take up 80%and lung adenocarcinoma(LUAD)represents more than 60%of non-small cell lung cancers(NSCLC)[2].In general,five treatment options are available for lung cancer treatment,including surgery,radiation,chemotherapy。

关 键 词：CHEMOTHERAPY 新靶点 NSCLC 肺腺癌 TREATMENT 

分 类 号：R734.2[医药卫生—肿瘤]